Ascendis Health

ASCENDIS HEALTH APPOINTS MARK SARDI AS NEW CHIEF EXECUTIVE

Johannesburg - Ascendis Health today announced the appointment of Mark Sardi as chief executive officer and an executive director with effect from 14 October 2019. Sardi (50) joins the healthcare group from House of Busby where he has been CEO since 2014.

September 2, 2019

Ascendis Health chairman Andrew Marshall said: “Mark has held senior leadership positions in investment banking, the pharmaceutical industry and the retail sector, and has a strong track record in strategic, operational and financial management in large listed and unlisted companies. “He has demonstrated his leadership ability in turning around complex organisations and is experienced in […]

ASCENDIS HEALTH SELLS BIOSCIENCES BUSINESSES FOR R480 MILLION

Johannesburg – Health and wellness group Ascendis Health is to sell the Efekto, Marltons and Afrikelp businesses within Ascendis Biosciences in a management buy-out led by RMB Ventures and Nedbank Private Equity for R480 million

May 2, 2019

The sale forms part of Ascendis Health’s divestment of non-core assets and businesses announced in September 2018. Chief executive officer Thomas Thomsen said: “Following our strategic business review last year the Biosciences division was considered as non-core to the group’s strategy and was identified for sale. While these Biosciences businesses are performing well, they serve […]

ASCENDIS HEALTH’S INTERNATIONAL GROWTH OFFSET BY WEAKER DOMESTIC PERFORMANCE

Johannesburg – South African-based international health and wellness business Ascendis Health today reported a 3% increase in revenue to R4 billion for the six months to December 2018 while normalised operating profit was 2% lower at R619 million.

March 18, 2019

International revenue rose by 7% to R2 billion and accounts for 50% of the group’s total sales. The tough consumer environment and weak sentiment in South Africa resulted in domestic revenue declining by 1%. The group’s gross margin strengthened by 260 basis points to 44.9%, mainly due to improved raw material pricing through strategic sourcing […]

SALE OF NON CORE ASSETS

Johannesburg – Ascendis Health has concluded a sale agreement of its pharmaceutical manufacturing facility in Isando, Gauteng, to Mylan, one of the world’s leading pharmaceutical companies, for R130 million.

December 20, 2018

The contemplated sale forms part of Ascendis Health’s non-core asset disposal programme announced earlier this year following management’s strategic business review. Chief executive officer Thomas Thomsen said: “After an extensive evaluation of our pharmaceutical manufacturing requirements we decided to sell the Isando plant owing to its low utilisation and to reduce the complexity of our […]